Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer

Journal of Association of Physicians of India

Volumn 54, Issue MAR., 2006, Pages 183-186

  Gupta, Sapna ^a   Tandon, V R ^a   Kapoor, B ^a   Gupta, A ^a   Gupta, G D ^a   Khajuria, V ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; BLOOD; BREAST TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; MIDDLE AGED;

ADULT; AGED; BREAST NEOPLASMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIGLYCERIDES;

EID: 33645151448     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Wolff AC, Davidson NE. Use of SERMS for the adjuvant therapy of early stage breast cancer. Ann NYA Sci 2001;949:80-8.
2. Bruning PF, Bonfrer JMG, Hart AAM, Jong-Bakker M, Linders D, Loon JV. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497-9.
3. Decensi A, Fontana V, Bruno S, et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996;14:434-40.
4. Joensuu H, Holli K, Oksanen H, Valavaara, R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000;63:225-34.
5. Miyauchi K, Sano M, Kimura M, et al. Effect of toremifene and tamoxifen on serum lipids in postmenopausal patients with breast cancer. Proc Am Soc Clin Oncol 2003;22:41.
6. Sharma D, Sharma U, Bhatnagar VB, Singh VS. A comparative effect of tamoxifen on serum lipid and lipoprotein profile in pre menopausal and postmenopausal women with breast carcinoma and associated risk of vascular complications. Ind J Med Sci 2001;55:37-40.
7. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-5.
8. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999;17:2633-8.
9. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer. Ann Oncol 2004;15:211-7.
10. Caleffi M, Fentiman IS, Clark GM, et al. Effect of tamoxifen on estrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocr 1988;119:335-9.
11. Stevensen JC. Mechanism whereby estrogens influence arterial health. Eur J Obstet Gynecol Reprod Bio 1996;5:39-42.
12. Brown WV. Introduction-special issue on hypercholesterolaemia. Am J Med 1997;2:1-2.
13. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67:26B-36B.
14. Sack MN, Rader DJ, Cannan RO. Estrogen and inhibition of oxidation of low density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
15. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risk. Arch Intern Med 1993; 153:598-615.
16. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126-31.